Valneva is eager to turn the page on Covid.
The Franco-Austrian biotech, specializing in travel vaccines, embarked on the development of an anti-Covid serum from the start of the epidemic.
The ace.
It accumulated setbacks last year, with the termination of the British order (100 million doses) and the reduction to the bare minimum of that of Europe (60 million).
If its vaccine finally obtained the green light from Brussels in June, it is a commercial failure: 1.2 million doses have been delivered to Europe and 1 million to Bahrain.
“
The health emergency was no longer the same and the States had already spent a lot of money on vaccines,
summarizes Peter Buhler, financial director of biotech.
Valneva has also suffered from being a small company, with fewer privileged contacts than a large laboratory.
A thinly veiled allusion to Sanofi, which Valneva has beaten in the race for the vaccine.
In vain.
Biotech finds itself with 8 million doses to sell.
“
He…
This article is for subscribers only.
You have 71% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
I ENJOY IT
Already subscribed?
Login
